Evening Brief: Can Cristiano Ronaldo's Polyphasic Sleep Be Emulated by the General Public?; Chinese Innovative Drugs Generate Nearly $100 Billion in Overseas Revenue in First Half of 2026, Signaling a Global Industry Leap

1. Can Ordinary People Imitate Cristiano Ronaldo's Segmented Sleep Method?

Cristiano Ronaldo’s “Polyphasic Sleep Method” Goes Viral OnlineRecently, Cristiano Ronaldo’s “polyphasic sleep method” has gone viral online, prompting many fans and fitness enthusiasts to follow suit. This sleep regimen was not created by Ronaldo himself but was proposed by sports sleep expert Nick Littlehales. Its core principle is based on the fact that a complete human sleep cycle lasts approximately 90 minutes. During periods of intense competition, Ronaldo sleeps five times a day, with each session lasting 90 minutes, totaling 7.5 hours of sleep per day. His bedroom is equipped with blackout curtains, temperature control, and electromagnetic shielding devices. He avoids blue light from mobile phones before bed and incorporates meditation and stretching to relax his nervous system. However, it is difficult for ordinary people to replicate such a sleep environment; typical home conditions can undermine the restorative benefits of polyphasic sleep, and merely mimicking the format may prove counterproductive. The standard for healthy adult sleep is 7–9 hours of continuous sleep per night. Ronaldo’s polyphasic sleep approach is suitable only for professional athletes under high-intensity schedules and professional monitoring. Individuals experiencing sleep problems should seek medical advice promptly to develop a personalized sleep schedule tailored to their needs.

2. Overseas Revenue from Innovative Drugs Nears $100 Billion in Half a Year! China’s Global Industrial Status in Innovative Pharmaceuticals Undergoes a Leap

According to statistics from PharmaCube, China’s innovative drug business development (BD) overseas achievements in 2026 have been remarkable. In the first half of the year, the total value of overseas transactions reached nearly $100 billion, specifically $99.7 billion, which is approximately twice that of 2024 and 73% of the 2025 figure. Among these, the total upfront payments for outbound licensing BD transactions amounted to around $5 billion, accounting for roughly 70% of the full-year total of the previous year. Industry experts predict that the annual transaction volume is poised to hit a new record high. With the concentrated closure of mega-deals valued in the billions, commercial models such as bulk procurement by multinational pharmaceutical companies, multi-pipeline asset bundling, and co-development (Co-Co) are gaining prominence. As a result, the global industrial status of China’s innovative drugs has undergone a significant leap, demonstrating strong development potential and international competitiveness, and gradually occupying a more important position in the global pharmaceutical market.

3. MindRank Secures $52 Million in Series B Funding; AI-Designed Weight-Loss Drug Enters Phase III Clinical Trials

MindRank Completes $52 Million Series B Financing, with Investment from Leading RMB and USD Funds; KaiCheng Capital Serves as Exclusive Financial AdvisorThe funding will be used to upgrade and iterate MindRank’s AI-driven drug discovery engine, the Molecule Arts Platform (MAP), enhance its multi-agent collaborative system and clinical data closed-loop, advance the Phase III clinical trials and commercialization of its self-developed oral small-molecule GLP-1 candidate MDR-001, and expand its pipeline of other differentiated innovative drugs. Founder Niu Zhangming believes that AI technology can disrupt traditional new drug development models. The MAP platform features a three-tier architecture: the AI design layer integrates multiple platforms to cover the entire drug development process; the wet-and-dry lab complementary experimental platform generates data to support model iteration; and the Clinical Pro clinical AI platform incorporates clinical feedback into the R&D system. This structure constitutes MindRank’s core competitive barrier, distinguishing it from other AI-driven pharmaceutical companies.

4. BriSTAR Immunotech Completes Over RMB 200 Million in Series C Financing, Accelerating the Deployment of Its Universal STAR-T and In Vivo Cell Therapy Platforms

On July 6, 2026, BriSTAR Immunotech (Beijing) announced the completion of its Series C financing round, raising over RMB 200 million. The round was led by Loyal Valley Capital, with Fudan Sci-Tech Innovation Fund as a co-investor. The funds will be primarily used to advance the registrational clinical development of YTS109, the core product of its universal STAR-T platform; accelerate the construction of its in vivo STAR-T technology platform; and establish its commercialization infrastructure and global intellectual property portfolio.

5. Insight Biotech Completes Tens of Millions in Pre-A+ Funding Round, Accelerating the Industrialization of Solid-State Nanopores

Guangzhou Insight Technology Co., Ltd. Completes Tens of Millions in Pre-A+ Financing, Invested by Shanlan Capital, Marking Two Rounds of Funding Within Six Months. The funds will be primarily allocated to the construction of testing and packaging production lines for solid-state nanopore chips, the development of detection products, and technological expansion in advanced semiconductor fields. Founded by a team of PhDs from prestigious universities, the company has independently established a technical chain spanning from chip design to signal analysis, forming high-consistency capabilities in the fabrication and detection of solid-state nanopores. Leveraging its solid-state nanopore technology, the company is developing a diversified application layout centered on “life information reading, advanced semiconductors, and brain-inspired intelligence,” with life information reading as the current core focus. It is about to launch a 32–96 channel solid-state nanopore single-molecule analysis platform to serve various scenarios.

6. AI Virtual Cell Company Huayuan Zhiyin Secures Tens of Millions in Seed Funding, with Investment from Shuimu Chuangtou

On July 7, AI-driven life sciences company Huayuan Zhiyin completed a seed funding round worth tens of millions of yuan, led by Shuimu Ventures, with no financial advisor disclosed. The funds will be used to build core competitive advantages in data, models, and clinical applications, accelerate collaboration and commercial deployment with top-tier Grade A tertiary hospitals, and advance the strategic layout “from a world model in the cellular domain to a Life Sciences OS.” Huayuan Zhiyin has established deep collaborations with multiple Grade A tertiary hospitals, creating closed-loop data systems and promoting application implementation across three key scenarios. Traditional AI drug discovery suffers from fundamental flaws, leading to significant losses during clinical stages. Huayuan Zhiyin chooses to predict drug efficacy responses in human cells before large-scale clinical trials, reconstructing the drug development evaluation system and establishing itself as the industry gold standard.